Pragma Bio (Formerly VastBiome)

PragmaBio operates at the intersection of genomic sequencing, artificial intelligence, and synthetic biology to address some of the most challenging immunologic disorders. The company focuses on discovering biomarkers and developing novel therapeutics by leveraging advanced technologies. PragmaBio serves clients in the healthcare and pharmaceutical sectors, offering solutions that range from biomarker discovery to therapeutic development. The company generates revenue through partnerships, research collaborations, and licensing agreements. By utilizing patient-derived clinical metadata and biospecimen samples, PragmaBio employs machine learning to predict viable biomarkers and therapeutic candidates. The business model also includes the production of small molecules via cell-free expression and high-throughput immune profiling assays for functional screening.

Keywords: genomic sequencing, artificial intelligence, synthetic biology, biomarkers, therapeutics, immunologic disorders, microbial molecules, machine learning, biomanufacturing, immune profiling.